Provided
SHL Medical, a global leader in advanced self-injection solutions, officially inaugurated its new state-of-the-art manufacturing facility in North Charleston, South Carolina. This expansion represents a significant US$220 million investment, contributing to the local economy and creating hundreds of new jobs in the region.
The grand opening was attended by South Carolina’s Governor Henry McMaster, North Charleston Mayor Reginald L. Burgess, and Swiss Embassy Consul General Urs Broennimann, underscoring the importance of the new facility in supporting SHL Medical’s US operations and enhancing its capacity to meet rising demand for autoinjectors.
Supporting demand and strengthening supply chains
The 360,000 ft² facility will produce SHL Medical’s advanced autoinjectors, which are used in high-demand treatments for conditions such as obesity, autoimmune disorders, and rare diseases. As the demand for GLP-1 therapies rises, the new facility ensures a reliable supply of these vital drug delivery devices to millions of patients across the US while also reducing lead times and transportation costs.
“This facility marks a key step in our global expansion and strengthens our ability to meet the increasing demand for autoinjectors,” said Ulrich Faessler, CEO of SHL Medical. “South Carolina offers a strong pipeline of skilled labor and a favorable business environment, enabling us to scale up production while contributing to the region's growth.”
Equipped with advanced injection molding technology and fully automated assembly lines, the new facility is designed to maintain the highest levels of quality and efficiency in manufacturing. This expansion complements SHL Medical’s established production sites in Taiwan and the upcoming facility in Switzerland, positioning the company as one of the few autoinjector manufacturers operating on three continents.
By leveraging its existing operations in Florida and recent acquisitions under SHL Advantec, the North Charleston site strengthens SHL Medical’s US presence, supporting large-scale production and advancing its mission to deliver world-class drug delivery solutions. The company is on track to deliver 1.5 billion devices to customers in 2025.
“We are proud to expand our US operations and support the local community,” said Kimberlee Steele, Managing Director North America at SHL Medical. “One of the most trusted autoinjector brands is now made in the USA, ensuring patients receive the essential devices they need to manage their health with independence.”
About SHL Medical
SHL Medical is a pioneering leader in self-injection solutions, such as autoinjectors. Driven by our core purpose of “enabling patients’ independence”, we partner with leading pharma and biotech companies to develop self-injection systems and digital solutions enhance patients’ treatment experience and quality of life. With over 5,000 employees located across our offices in Switzerland, USA, Sweden, and Taiwan, we rely on our comprehensive in-house manufacturing capabilities to provide end-to-end services, from design, development, to final assembly, labeling, and packaging. For additional information, visit www.shl-medical.com.
